• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Intermittent montelukast (singulair) fails to reduce medical visits in children with wheezing [WAIT trial]

byXiaozhou Liu
September 9, 2014
in Chronic Disease, Pediatrics, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Overall there was no reduction in unscheduled medical attendances for wheezing in children that received intermittent montelukast compared to children that received placebo.

2. The study identified a subset of population with the 5/5 ALOX5 promoter genotype that might be montelukast-responsive.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Wheezing in the young pediatric population is commonly due to asthma, viral infections of the respiratory tract, and allergies, among other causes. While the majority of episodes are self-limited, acute respiratory distress that requires hospitalization is occasionally seen. Montelukast is effective in the subpopulation of asthmatics whose asthma have a leukotriene component. Results of a multicenter, randomized controlled trial (WAIT trial) were published in Lancet today. Compared to placebo, intermittent montelukast was not associated with reduction in unscheduled medical attendances overall. Subgroup analyses did reveal heterogeneity where children of a particular genotype appeared to have benefited from montelukast and had fewer medical attendances. The study was well-designed and adequately powered, with over 1,300 participants. Additional research is needed to allow further treatment stratification based on genotypes.

The study was funded by the Medical Research Council (UK) and National Institute for Health Research.

Click to read the study, published today in The Lancet

Relevant Reading: Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1—5 years: randomised controlled trial

RELATED REPORTS

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

In-Depth [randomized controlled trial]: WAIT is a multi-center, randomized, placebo-controlled trial that assessed whether intermittent montelukast reduced unscheduled medical attendances for wheezing in the pediatric population. A total of 1358 children were stratified to either a 5/5 or 5/x+x/x ALOX5 promoter genotype, then randomized 1:1 to receive either intermittent montelukast or placebo for 12 months. Parents were advised to administer montelukast or placebo at the onset of each viral cold or wheezing episode. The ALOX5 gene encodes 5-lipoxygenase, which is the rate-limiting enzyme in the cysteinyl leukotriene biosynthetic pathway. The primary endpoint was the number of unscheduled medical attendances for wheezing episodes.

Overall, no significant difference was observed in mean medical attendances between the montelukast group and the placebo group (2.0, standard deviation SD, 2.6, vs. 2.3, SD 2.7; p=0.06). Additionally, no significant difference was recorded between the montelukast and placebo groups for the number of children who had at least one unscheduled medical attendance for wheezing episodes the number of wheezing episodes, or the duration of wheezing episodes. There was a slight increase in time to first hospital admission with montelukast (p=0.04).

In subgroup analyses, children of the 5/5 ALOX5 promoter genotype had fewer unscheduled medical attendances for wheezing episodes (2.0, SD 2.7 vs 2.4, SD 3.0, p=0.01). This possible benefit was not observed in children of the 5/x+x/x ALOX5 promoter genotype.

More from this author: New dengue fever vaccine effective in phase 3 trial, Insulin pumps more effective than multiple daily injections in type II diabetics [OpT2mise trial], Heart attack hospitalization rate in China quadruples from 2001-2011, Vitamin D supplementation does not reduce risk of falls, ¹⁸F-FDG PET brain imaging could predict recovery in vegetative patients

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: asthmamontelukast
Previous Post

Fish oil lowers seizure frequency in drug-resistant epilepsy

Next Post

Key drugs reduce fracture risk in osteoporosis

RelatedReports

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Emergency

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

June 21, 2022
Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

April 5, 2022
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

March 9, 2022
Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial
Chronic Disease

Itepekimab provides beneficial effects for patients with moderate-to-severe asthma.

November 12, 2021
Next Post
Repeat bone mineral density testing may not improve prediction of fracture outcomes

Key drugs reduce fracture risk in osteoporosis

Updated guidelines for management of sickle cell disease released

Updated guidelines for management of sickle cell disease released

Cost-related medication nonadherence associated with increased ED utilization

Dementia patients frequently on medications with minimal benefit

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.